Overcoming the Pregnane X Receptor Liability: Rational Design to Eliminate PXR-Mediated CYP Induction

In silico structural features of the CgNR5A: CgDAX complex and its role in regulating gene expression of CYP target genes in Crassostrea gigas

Contamination of aquatic environments has been steadily increasing due to human activities. The Pacific oyster Crassostrea gigas has been used as a key species in studies assessing the impacts of contaminants on human health and the aquatic biome. In this context, cytochrome P450 (CYPs) play a crucial role in xenobiotic metabolism. In vertebrates many of these CYPs are regulated by nuclear receptors (NRs) and little is known about the NRs role in C. gigas. Particularly, the CgNR5A represents a homologue of SF1 and LRH-1 found in vertebrates. Members of this group can regulate genes of CYPs involved in lipid/steroid metabolism, with their activity regulated by other NR, called as DAX-1, generating a NR complex on DNA response elements (REs). As C. gigas does not exhibit steroid biosynthesis pathways, CgNR5A may play other physiological roles. To clarify this issue, we conducted an in silico investigation of the interaction between CgNR5A and DNA to identify potential C. gigas CYP target genes. Using molecular docking and dynamics simulations of the CgNR5A on DNA molecules, we identified a monomeric interaction with extended REs. This RE was found in the promoter region of 30 CYP genes and also the NR CgDAX. When the upstream regulatory region was analyzed, CYP2C39, CYP3A11, CYP4C21, CYP7A1, CYP17A1, and CYP27C1 were mapped as the main genes regulated by CgNR5A. These identified CYPs belong to families known for their involvement in xenobiotic and lipid/steroid metabolism. Furthermore, we reconstructed a trimeric complex, previously proposed for vertebrates, with CgNR5A:CgDAX and subjected it to molecular dynamics simulations analysis. Heterotrimeric complex remained stable during the simulations, suggesting that CgDAX may modulate CgNR5A transcriptional activity. This study provides insights into the potential physiological processes involving these NRs in the regulation of CYPs associated with xenobiotic and steroid/lipid metabolism.

UV filter benzophenone-2: Effects on zebrafish (Danio rerio) cytochrome P450

Benzophenone-2 (2,2', 4,4'- Tetrahydroxybenzophenone; BP-2) is widely used as a sunscreen in Personal and Care Products (PCPs) for protection against ultraviolet (UV) radiation. The effects of BP-2 on random-sex adult zebrafish (Danio rerio) cytochrome P450 (CYP450) were studied. The main goal was to investigate the detoxification mechanisms underlying the adverse consequences of exposure to xenobiotic chemicals such as BP-2. Total protein content, CYP450 content, and erythromycin N-demethylase (ERND) activity were evaluated as indicators of protein CYP3A expression. Five sets of pooled random-sex adult zebrafish were exposed to 0.0, 0.1, 5.0, and 10.0 mg/L of BP-2 to evaluate their acute and chronic toxicity (4 and 15 days, respectively). ERND activity was significantly increased in the chronic toxicity group compared to that in the control group, whereas CYP450 remained unchanged. The results suggest a sufficiently fast catalytic process that does not alter the total CYP450 content. It implies a mediation of CYP450 3A induction by BP-2 and the pregnane X receptor ligand-binding domain (PXR LBD) interaction. Ligand-protein interactions were confirmed via in silico docking with AutoDock Vina. Further computational studies indicate BP-2 potential binding affinity for the Estrogen receptor alpha ligand binding domain (ERα LBD). These results suggest that CYPs effects may result in significant toxicity in the zebrafish. Our study highlights the importance of studying biomarkers in aquatic organisms to assess xenobiotic exposure and the potential toxicity of UV filters to humans.

Jean D, Malinowski J, DeBenedetto M, Moebius D, Payette J, Vargas R, Yeoman J, Motani A, Reagan J, Malik FI, Morgan BP. Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility

Cardiac myosin activation has been shown to be a viable approach for the treatment of heart failure with reduced ejection fraction. Here, we report the discovery of nelutroctiv (CK-136), a selective cardiac troponin activator intended for patients with cardiovascular conditions where cardiac contractility is reduced. Discovery of nelutroctiv began with a high-throughput screen that identified compound 1R, a muscle selective cardiac sarcomere activator devoid of phosphodiesterase-3 activity. Optimization of druglike properties for 1R led to the replacement of the sulfonamide and aniline substituents which resulted in improved pharmacokinetic (PK) profiles and a reduced potential for human drug-drug interactions. In vivo echocardiography assessment of the optimized leads showed concentration dependent increases in fractional shortening and an improved pharmacodynamic window compared to myosin activator CK-138. Overall, nelutroctiv was found to possess the desired selectivity, a favorable pharmacodynamic window relative to myosin activators, and a preclinical PK profile to support clinical development.